RxDoctor Payments Data

Nripen Dontineni, MD

Internal Medicine · South Plainfield, NJNPI 1790123024

Payments from drug & device makers

$3,186in general payments, 2019–2025

Across 107 payments — averaging $29.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Novo Nordisk$691
  • Amgen$199
  • AstraZeneca$171
  • Bayer$142
  • Madrigal Pharmaceuticals$135
  • plus $665 from 11 others

What the payments were for

  • Food & beverage$3,186100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,186 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$96,993
Medicare patients
276
Services billed
1,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$93,720
TradjentaLinagliptin60$35,700
XareltoRivaroxaban33$31,591
JanuviaSitagliptin Phosphate36$28,382
JardianceEmpagliflozin17$28,148
OzempicSemaglutide18$27,347
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$23,978
FarxigaDapagliflozin Propanediol19$17,965
EntrestoSacubitril/Valsartan12$13,620
MultaqDronedarone Hcl12$9,604
Atorvastatin Calcium486$5,587
Amlodipine Besylate490$4,495
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$4,177
Metoprolol Succinate262$4,031
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$3,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$93,720166 claims
MerckJanuvia$25$28,38236 claims
Novo NordiskOzempic$691$27,34718 claims
GSKTrelegy Ellipta$1,182$23,97832 claims
AstraZenecaFarxiga$171$17,96519 claims
NovartisEntresto$14$13,62012 claims
AbbVieSynthroid$101$1,19213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in South Plainfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →